For 90 seconds on a late April morning, one of the busiest airports in America went dark. Air traffic controllers at Newark Liberty International Airport lost radar and radio contact…
Posts published in “Wall Street Wire”
Breakthrough Phase 3 topline data released today shows 58% reduction in surgical infections as analysts maintain $11-$13 price targets on $2.89 stock PolyPid Ltd. (NASDAQ: PYPD)* just announced results that…
BiomX Inc. (NYSE: PHGE)* has achieved something that eluded Big Pharma for decades—successful clinical trials using viruses to treat life-threatening infections that no longer respond to antibiotics. With positive Phase…
Silexion Therapeutics* stands at the cutting edge of cancer’s final frontier – the notorious KRAS mutation that drives some of medicine’s deadliest tumors. Their groundbreaking SIL-204 therapy isn’t just showing…
Actelis Networks (NASDAQ: ASNS)* demonstrated solid progress in Q1 2025, maintaining stable quarterly revenue while significantly improving gross margins to 35% (up from 30% in Q1 2024) and reducing net…
NeuroSense Therapeutics (NASDAQ: NRSN)* announces today it has successfully scaled-up PrimeC production to commercial levels, removing the final technical barrier before potential Canadian market entry worth $100-150M The Bottom Line…
Inspira Technologies (NASDAQ: IINN)* just announced something that investors may want to pay close attention to. The Company announced that Israel’s largest healthcare provider has approved its revolutionary life-support system…
Palatin Technologies (NYSE American: PTN)* announced today a significant $11.5 million financing deal expected to close May 8, with potential for an additional $11.5 million through milestone-related warrants. This financing,…
THE BOTTOM LINE: Inspira Technologies (NASDAQ: IINN)* is challenging the $19 billion mechanical ventilation industry with a revolutionary approach: delivering oxygen directly to the blood instead of forcing air into…
The Bottom Line: NeuroSense (NASDAQ: NRSN)* is on the verge of potentially transforming ALS treatment with PrimeC, a novel drug combo showing remarkable 36% reduction in disease progression and 43%…